• Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations.
• This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments.
• The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners.

For investors tracking Guardant Health (NasdaqGS:GH), this FDA decision adds fresh clinical relevance to a stock that has already seen very large gains of about 273.2% over three years and 113.5% over the past year. Shares recently closed at $89.52, with a 7.7% return over the past week, while returns over 30 days and year to date show declines of 4.6% and 12.0% respectively.

This new label expansion for Guardant360 CDx could influence how you think about Guardant Health’s role in precision oncology and its relationships with drug developers. The development also gives more real world data points to watch around test adoption, potential revenue mix shifts, and how the company converts diagnostic approvals into broader platform use over time.

Stay updated on the most important news stories for Guardant Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Guardant Health.

Investor Checklist

Quick Assessment

• ✅ Price vs Analyst Target: At US$89.52 against a consensus target of US$128.33, the stock trades about 30% below analyst expectations.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 48.1% below fair value, classifying Guardant Health as undervalued.
• ❌ Recent Momentum: The 30 day return of about 4.6% shows recent share price weakness despite the strong 12 month move.

There is only one way to know the right time to buy, sell or hold Guardant Health. Head to Simply Wall St's company report for the latest analysis of Guardant Health's Fair Value.

Key Considerations

• 📊 The new FDA approval ties Guardant360 CDx to another targeted breast cancer therapy, which can strengthen the test's role in treatment selection.
• 📊 Keep an eye on adoption of VEPPANU, testing volumes for Guardant360 CDx, and how any incremental revenue lines up against ongoing losses and a negative net margin of about 42%.
• ⚠️ The company remains unprofitable with negative shareholders' equity, so investors may want to weigh balance sheet risk against the potential from new companion diagnostic partnerships.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Guardant Health analysis. Alternatively, you can visit the community page for Guardant Health to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.